Latent Tuberculosis in India: An Overview.
dormancy
immune suppression
including latency
latent tuberculosis
persistence
tuberculosis
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
15
11
2022
accepted:
02
03
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Treatment of latent tuberculosis infection (LTBI) is essential for tuberculosis (TB) eradication. LTBI patients serve as a reservoir for active TB cases. The WHO's End TB Strategy now prioritises the detection and treatment of LTBI. A comprehensive approach focused on integrated LTBI control is required to accomplish this goal. This review aims to summarise what we know about LTBI in the existing literature, its prominence, diagnostic strategies, and new interventions to alert people of its occurrence and symptoms. We used Medical Subject Heading (MeSH) phrases to search for published publications on the English language in PubMed, Scopus, and Google Scholar. To provide clarity and impact, we examined several government websites to identify the most effective and current treatment regimens. LTBI is a spectrum of infections, such as intermittent, transitory, or progressive, with early, subclinical, and ultimately active TB cases. The global burden of LTBI cannot be firmly established because no "gold-standard" test exists. Screening is advised for high-risk individuals, such as immigrants, occupants and staff members of congregate living facilities, and those who are HIV-positive. The most reliable form of LTBI screening is still the targeted tuberculin skin test (TST). Although LTBI therapy is challenging, for India to become TB-free, it must first focus on testing and treating LTBI. The government should focus on generalising the new diagnostic criteria and adopting a more specific treatment known to all to eliminate TB once and for all.
Identifiants
pubmed: 37009383
doi: 10.7759/cureus.35706
pmc: PMC10065373
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
e35706Informations de copyright
Copyright © 2023, Vishwakarma et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Microbiol Mol Biol Rev. 2014 Sep;78(3):343-71
pubmed: 25184558
Mayo Clin Proc. 2011 Apr;86(4):348-61
pubmed: 21454737
Emerg Microbes Infect. 2016 Feb 03;5:e10
pubmed: 26839146
Am J Epidemiol. 2001 Feb 15;153(4):381-5
pubmed: 11207156
Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47
pubmed: 10764341
Eur Respir J. 2016 Nov;48(5):1411-1419
pubmed: 27390280
Infection. 2009 Apr;37(2):80-6
pubmed: 19308318
Clin Microbiol Rev. 2014 Jan;27(1):3-20
pubmed: 24396134
JAMA. 1999 Aug 18;282(7):677-86
pubmed: 10517722
Arch Immunol Ther Exp (Warsz). 2010 Feb;58(1):7-14
pubmed: 20049645
Int J Tuberc Lung Dis. 2001 Jul;5(7):589-93
pubmed: 11469255
J Gen Microbiol. 1970 Sep;63(1):41-8
pubmed: 5500025
Eur Respir J. 2016 Mar;47(3):919-28
pubmed: 26677940
Respirology. 2018 Oct;23(10):893-900
pubmed: 29901251
PLoS Med. 2016 Oct 25;13(10):e1002152
pubmed: 27780211
J Infect Dis. 2002 Feb 1;185(3):401-4
pubmed: 11807725
Bull World Health Organ. 1982;60(4):555-64
pubmed: 6754120
Indian J Community Med. 2018 Jan-Mar;43(1):1-4
pubmed: 29531429
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):148-50
pubmed: 26884490
J Biol Chem. 2014 Oct 31;289(44):30190-30195
pubmed: 25202011
Indian J Med Res. 2011 Mar;133:257-66
pubmed: 21441678
Front Immunol. 2020 Sep 10;11:2006
pubmed: 33013856
Ann Intern Med. 2008 Mar 4;148(5):325-36
pubmed: 18316751
Am J Respir Crit Care Med. 2016 Aug 15;194(4):501-9
pubmed: 26866439
Am Fam Physician. 2009 May 15;79(10):879-86
pubmed: 19496388
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):273-89
pubmed: 16545981
Respir Res. 2010 Dec 03;11:169
pubmed: 21126375
Respirology. 2010 May;15(4):603-22
pubmed: 20409026
Can Commun Dis Rep. 2017 Mar 02;43(3-4):62-66
pubmed: 29770066
Antimicrob Agents Chemother. 1972 Jul;2(1):29-35
pubmed: 4208567